Riferimenti bibliografici
  1. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003;38:S38-S53.
  2. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-72.
  3. Gines P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-1654.
  4. Popper H, Uenfriend S. Hepatic fibrosis. Correlation of biochemical and morphologic investigations. Am J Med 1970;49:707-721.
  5. Schaffner F, Klion FM. Chronic hepatitis. Annu Rev Med 1968;19:25-38.
  6. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.
  7. Cotran R, Kumar V, Collins T (Eds). Tissue Repair: cellular growth, fibrosis, and wound healing. Robbin's Pathological Basis of Disease 1999 6th ed., WB Saunders Co., Philadelphia, 88-112.
  8. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000;279:G245-G249.
  9. Vinas O. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 2003;38:919-929.
  10. Marra F. Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 1999;31:1120-1130.
  11. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.
  12. Carosi G, Rizzetto M, Alberti A, et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011;43:259-65.
  13. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
  14. Goldin RD, Goldin JG, Burt AD, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996;25:649-54.
  15. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
  16. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009;50:1-3.
  17. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on the histological evaluation of chronic hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
  18. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000;133:665-675.
  19. Wai CT, Greenson JK, Fontana RJ, et al. A simple non invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
  20. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. Aids 2003;17:721-725.
  21. Myers RP, De Torres M, Imbert-Bismut F, et al. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 2003;48:146-153.
  22. Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-454.
  23. Poynard T, Morra R, Halfon P, et al. Meta-analyses of Fibrotest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7:40.
  24. Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009;49(6):1821-7.oeoe
  25. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29:1705-13.
  26. Roulot D, Czernichow S, Le Clesiau H, et al. Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. J Hepatol 2008;48:606-13.
  27. Foucher J, Castera L, Bernard PH, et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol 2006;18:411-412.
  28. Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007;14:360-9.
  29. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117.
  30. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51.
  31. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893.
  32. Marcellin P, Buti M, Gane EJ, et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011 (suppl);54:1011A.
  33. Friedman SL and Bansal MB Reversal of Hepatic Fibrosis - Fact or Fantasy? Hepatology 2006;43 (Suppl 1):S82-S88.